Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Añadir filtros








Intervalo de año
1.
Artículo en Inglés | IMSEAR | ID: sea-143528

RESUMEN

We report an elderly male who presented with history of chronic diarrhoea. The patient underwent colonoscopy and CT scan of the abdomen which strongly suggested tuberculosis; however histopathology showed presence of budding forms of Histoplasma capsulatum. The patient was started on oral itraconazole on which he improved remarkably. ©


Asunto(s)
Abdomen/patología , Antifúngicos/uso terapéutico , Diagnóstico Diferencial , Histoplasmosis/diagnóstico , Histoplasmosis/tratamiento farmacológico , Histoplasmosis/microbiología , Humanos , Itraconazol/uso terapéutico , Masculino , Persona de Mediana Edad , Tuberculosis Gastrointestinal/diagnóstico , Tuberculosis Gastrointestinal/patología
2.
Artículo en Inglés | IMSEAR | ID: sea-92852

RESUMEN

OBJECTIVES: 1. To compare the protective antibody titres on day 14, 30 and 90 after giving intramuscular (IM) injections of PCECV and subcutaneous injections of Nervous Tissue Vaccine. 2. To compare the immunogenicity and safety of PCECV and NTV. METHODS AND MATERIALS: The study enrolled cases in three groups.Group 'C' or control group: (n = 38) : This group comprised of 38 normal healthy volunteers without dog-bite. Group 'A' (n = 102): This group included cases of dog-bite fulfilling inclusion/exclusion criteria. Each one of Group A and C were given PCECV as post exposure treatment (PET) on day 0-3-7-14-30 and 90. Group 'B' (n = 50): This group included 50 cases of dog-bite who received NTV. The rabies virus neutralizing antibody titres were estimated by RFFIT (Rapid Fluorescent Focus Inhibition Test) on day 0, 14, 30 and 90 days. 45 recipients of PCECV were re-tested for persistence of Protective Antibodies at the end of 1 year. RESULTS: Of these 37, 91 and 45 cases were evaluable in Groups C, A and B respectively. The antibody titres in Groups A, B, C were 13.4, 3.2, 22.8 IU/ml respectively; the protective titre being 0.5 IU/ml.5% PCECV recepients had delayed response on day 30.14% of NTV recepients did not seroconvert. CONCLUSIONS: The Immunogenicity, Reactogenicity and safety of PCECV is well established. 5% of PCECV receipients showed a delayed sero conversion. 14% of NTV receipients did not sero convert at all.Therefore it is desirable to estimate antibody titres on day 14 after vaccination. If difficult, then all the cases of animal bite must receive passive immunization with rabies immunoglobulins.


Asunto(s)
Adulto , Anciano , Animales , Anticuerpos Antivirales/sangre , Mordeduras y Picaduras/terapia , Embrión de Pollo/inmunología , Grupos Control , Perros , Humanos , Esquemas de Inmunización , Inmunización Pasiva , Inyecciones Intramusculares , Inyecciones Subcutáneas , Persona de Mediana Edad , Rabia/inmunología , Vacunas Antirrábicas/administración & dosificación , Virus de la Rabia/inmunología , Factores Sexuales , Factores de Tiempo , Vacunación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA